Cost-Effectiveness of Escalating to Natalizumab or Switching Among Immunomodulators In Relapsing-Remitting Multiple Sclerosis In Italy. Furneri G, Santoni L, Ricella C, Prosperini L Value Health. 2015 Nov; 18(7):A695. Epub 2015 Oct 20. PMID: 26533897. Abstract CommentRecommendBookmarkWatch